1 – 10 of 92
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2016
-
Mark
Risk of male breast cancer in users of testosterone 5a reductase inhibitors
2016) 2016 Annual Meeting of the American Society of Clinical Oncology In Journal of Clinical Oncology 34(Suppl 15).(
- Contribution to journal › Published meeting abstract
-
Mark
Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial.
(
- Contribution to journal › Article
- 2015
-
Mark
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation.
(
- Contribution to journal › Article
-
Mark
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
(
- Contribution to journal › Article
-
Mark
Ewing Sarcoma: Current Management and Future Approaches Through Collaboration.
(
- Contribution to journal › Scientific review
-
Mark
Stable Peptide of the Endogenous Opioid Enkephalin Precursor and Breast Cancer Risk.
(
- Contribution to journal › Article
-
Mark
Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish-Swedish Population-Based Study.
(
- Contribution to journal › Article
- 2014
-
Mark
Cyclophosphamide Compared With Ifosfamide in Consolidation Treatment of Standard-Risk Ewing Sarcoma: Results of the Randomized Noninferiority Euro-EWING99-R1 Trial.
(
- Contribution to journal › Article
-
Mark
t(14;18) Translocation: A Predictive Blood Biomarker for Follicular Lymphoma
(
- Contribution to journal › Article
-
Mark
Collection and Use of Family History in Oncology Clinics.
(
- Contribution to journal › Letter